Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Tongjitang Chinese Medicine Reaches De-listing Deal

publication date: Nov 2, 2010
Tongjitang Chinese Medicines will be taken private by group comprised of its Chairman and Fosun Industrial at a price of $4.50 per ADS. The offer was originally made in April of this year. The result was never really in doubt, as Xiaochun Wang, Chairman and CEO of Tongjitang, owns 51% of the company, and Fosun controls 32%, giving them a combined 83% stake in the company. More details....

Stock Symbol: (NYSE: TCM)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital